Santos Garcia, DiegoFernandez Pajarin, GustavoOropesa-Ruiz, Juan ManuelEscamilla Sevilla, FranciscoRahim Lopez, Raul Rashid AbdulMuñoz Enriquez, Jose Guillermo2023-05-032023-05-032022-03-10Santos García D, Fernández Pajarín G, Oropesa-Ruiz JM, Escamilla Sevilla F, Rahim López RRA, Muñoz Enríquez JG. Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study. Brain Sci. 2022 Mar 12;12(3):383.2076-3425http://hdl.handle.net/10668/20851Patients with Parkinson’s disease (PD) can improve some non-motor symptoms (NMS) after starting treatment with opicapone. The aim of this study was to analyze the effectiveness of opicapone on global NMS burden in PD. OPEN-PD (Opicapone Effectiveness on Non-motor symptoms in Parkinson’s Disease) is a prospective open-label single-arm study conducted in 5 centers from Spain. The primary efficacy outcome was the change from baseline (V0) to the end of the observational period (6 months ± 30 days) (V2) in the Non-Motor Symptoms Scale (NMSS) total score. Different scales were used for analyzing the change in motor, NMS, quality of life (QoL), and disability. Thirty-three patients were included between JUL/2019 and JUN/2021 (age 63.3 ± 7.91; 60.6% males; 7.48 ± 4.22 years from symptoms onset). At 6 months, 30 patients completed the follow-up (90.9%). The NMSS total score was reduced by 27.3% (from 71.67 ± 37.12 at V0 to 52.1 ± 34.76 at V2; Cohen’s effect size = −0.97; p = 0.002). By domains, improvement was observed in sleep/fatigue (−40.1%; penAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Parkinson’s diseaseeffectivenessnon-motor symptomsopen-label studyopicaponeParkinson DiseaseDyskinesiasopicaponeApathyFollow-Up StudiesFatigueresearch article35326339open accessApatíaDiscinesiasEnfermedad de ParkinsonEstudios de SeguimientoFatiga10.3390/brainsci12030383PMC8945982https://www.mdpi.com/2076-3425/12/3/383/pdf?version=1647083046https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945982/pdf